Panel, don oconnell, the assistant secretary for preparedness and response. Rochelle walensky the director of the center for Disease Control and dr. Robert califf the commissioner of the food and drug administration. On our second panel we will hear from a doctor and Robert Wiseman and martin mccarrick. We have two very important panels. Let me begin by thanking all of the folks that run the first panel. All of us know that the last three years have been unprecedented in our lifetimes. We dealt with the worst Public Health crisis in 100 years. I want to think all of you under those difficult circumstances for the work you did for the American People. Today, our job is to take a look at at where we are today in terms of where we are preparing, god forbid, for another pandemic. And, the need to reauthorize the pandemic preparedness act later this year. I want to take the opportunity to acknowledge the previous leadership on the bill from senator murray, chair of the committee, and senato
Emergencies. Did you see director warned about the implications of the Current Public Health emergency depending on 11th but sent Health Committee also hears from commissioner about Lessons Learned from the covid19 pandemic. This is just over two hours 10 minutes. Rusmac hey, thank you. The Senate Committee on Health Education and pagers will come to order. This afternoon we are going to hear from two panels. We are going to hear from our first panel the assistant secretary for preparedness and response. The shot will instigate the director centers for Disease Control and doctor robert the commissioner for food and drug administration. Our second panel we will be hearingat from them will hear fm Robert Wiseman and martin carey we have two very, very important panels. Let me begin by thanking all of the folks who were on the first panel. All of us know the last three years have been unprecedented in our lifetimes where we with the worst Public Health crisis 100 years at the thank all of
The Cellular, Tissue, and Gene Therapies Advisory Committee of the FDA is meeting tomorrow, Tuesday, October 31, 2023, to review a Biologics License Application by Vertex Pharmaceuticals Inc. for.
Switzerland - CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the.
This week, CMS issued a RFI on Access to Care and Coverage in Medicaid and CHIP, and HRSA awarded $55 million to increase health care access through virtual care.